These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 20020666

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Mechanisms of drug resistance in hematologic malignancies.
    Dalton WS.
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):3-8. PubMed ID: 9408955
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Farnesyl transferase inhibition in hematologic malignancies.
    Karp JE.
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S37-40. PubMed ID: 16280111
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Procarbazine in haematology: an old drug with a new life?
    Massoud M, Armand JP, Ribrag V.
    Eur J Cancer; 2004 Sep; 40(13):1924-7. PubMed ID: 15315798
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
    Tsimberidou AM, Alvarado Y, Giles FJ.
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
    [Abstract] [Full Text] [Related]

  • 31. Assessing the effects of treatments for hematological malignancies on prepubertal growth.
    Pearce MS.
    Pediatr Hematol Oncol; 2000 Sep; 17(6):441-3. PubMed ID: 10989463
    [No Abstract] [Full Text] [Related]

  • 32. New sources of drugs for hematologic malignancies.
    Sukhai MA, Spagnuolo PA, Weir S, Kasper J, Patton L, Schimmer AD.
    Blood; 2011 Jun 23; 117(25):6747-55. PubMed ID: 21511957
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Asparagus in asparaginase therapy?].
    März W, Unger C.
    Med Monatsschr Pharm; 1999 Dec 23; 22(12):393. PubMed ID: 10628150
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
    Chase A, Cross NC.
    Clin Sci (Lond); 2006 Oct 23; 111(4):233-49. PubMed ID: 16961463
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?
    Cierpicki T, Grembecka J.
    Immunol Rev; 2015 Jan 23; 263(1):279-301. PubMed ID: 25510283
    [Abstract] [Full Text] [Related]

  • 39. [Ambulatory chemotherapy in hematology. A challenge ...].
    Montagne C, Duran B.
    Soins; 1996 Sep 23; (608):62-8. PubMed ID: 8954491
    [No Abstract] [Full Text] [Related]

  • 40. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S, Fenaux P, Ludwig H, O'dwyer M, Sanz M.
    Curr Med Res Opin; 2005 Mar 23; 21(3):403-11. PubMed ID: 15811209
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.